Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SULGEN Spray D. pteronyssinus for house dust mite allergic rhinitis/rhinoconjunctivitis
2021-005169-41Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Nov 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of dermatophagoides pteronyssinus in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy (2 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Primary efficacy endpoint. Started Nov 2022; status: completed.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2021-005169-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005169-41.